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ABSTRACT 
Atherosclerosis is increasingly recognized as a chronic inflammatory disease. Moreover, 
endotoxin release into the circulation is a potential source of inflammation, and represents an 
important target for intervention directed towards stemming of cardiovascular morbidity and 
mortality in chronic kidney disease (CKD) patients. Although previous studies have shown that 
elevated plasma endotoxin levels were associated with the risk of atherosclerosis, a direct link 
between endotoxaemia and atherosclerosis is yet to be fully elucidated. This study investigated 
endotoxaemia across the spectrum of South African CKD patients and also determined the pro-
inflammatory effects of endotoxin that are relevant to the development of subclinical 
atherosclerosis in CKD patients. 
A prospective cross-sectional study of 120 CKD patients was carried out, comprising 40 
each of peritoneal dialysis (PD), haemodialysis (HD) and stage 3 chronic kidney disease 
(CKD), attending the Charlotte Maxeke Johannesburg Academic Hospital, South Africa; and a 
comparator cohort of 40 age- and sex-matched controls. Endotoxin levels were measured and 
the results compared with serum lipopolysaccharide binding protein (LBP), serum CD14 
(sCD14), interleukin-8 (IL-8), monocyte chemoattractant protein-1 (MCP-1), oxidized LDL, 
interleukin-6 (IL-6), C-reactive protein (CRP), transforming growth factor-β (TGF-β), carotid 
intima media thickness (CIMT) and plaque occurrence (measured by B-mode ultrasound), and 
echocardiographic parameters. Bio-impedance spectroscopy was carried out using a body 
composition monitor (BCM) to assess fluid and nutritional status. Inflammatory cytokines 
including TGF-β1 and IL-6 were genotyped, and the genotype frequencies compared to the 
serum concentrations of the cytokines. Data was analysed using the statistical package for social 
sciences (SPSS) version 16.  
Volume overload and circulating endotoxaemia were common across the spectrum of 
CKD patients, and were aggravated by worsening kidney function. Endotoxins levels correlated 
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with both absolute overhydration (r=0.513, p<0.001) and percentage overhydration to 
extracellular water (OH/ECW%) (r=0.490, p<0.001). Carotid intima media thickness was 
significant higher among CKD patients compared to the controls (0.58 ± 0.12 versus 0.45 ± 0.05 
mm; p<0.001); CIMT was 0.63 ± 0.12; 0.56 ± 0.09 and 0.56 ± 0.12 mm in PD, HD and CKD 
stage 3 patients respectively. Carotid intima media thickness correlated with overhydration 
(r=0.442, p<0.001) and OH/ECW% (r=0.421, p<0.001). The risk of atherosclerosis was 
associated with serum levels of endotoxins (odds ratio: 2.34; confidence interval: 1.26-4.35, 
p=0.007), with excess risk confined to the group with high endotoxin levels. The risk of 
subclinical atherosclerosis was predicted by high concentrations of sCD14, IL-8 or MCP-1. 
Patients with high levels of circulating endotoxaemia in combination with high levels of sCD14, 
IL-8 or MCP-1 showed markedly elevated risk of atherosclerosis. The lowest Oxidized LDL 
levels were significantly higher in patients with carotid plaques compared to patients without 
carotid plaques (472.6 ± 104.6 versus 348.6 ± 110.9 ng/ml, p=0.012). Oxidized LDL showed a 
strong association with CIMT (r=0.664, p<0.001) among non-dialytic CKD patients. TGF-β 
isoform were present in lower concentrations in haemodialysis patients compared to the PD, 
CKD and controls. TGF-β concentrations were significantly lower in the patients with 
subclinical atherosclerosis compared to patients without atherosclerosis (TGF-β1: 4.1 × 104 ± 
1.5 × 10
4
 versus 5.9 × 10
4 
± 1.6 × 10
4
 pg/ml, p<0.001; TGF-β2: 1.6 × 103 ± 0.3 × 103 versus 1.8 
× 10
3 
± 0.2 × 10
3
 pg/ml, p<0.001;  and TGF-β3: 4.2 × 102 ± 0.9 × 102 versus 5.3 × 102 ± 1.1 × 
10
2
 pg/ml, p<0.001). TGF-β isoforms had an inverse relationship with CIMT (TGF-β1: 
r=−0.562, p<0.001; TGF-β2: r=−0.477, p<0.001; TGF-β3: r=−0.442, p<0.001). There was 
significant association between IL6 polymorphisms (−174G/G and −174G/C) and elevated 
serum IL-6 levels in CKD patients. 
Volume overload and circulating endotoxaemia were common across the spectrum of 
CKD patients. Volume overload was associated with the severity of kidney failure, 
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inflammation, malnutrition, atherosclerosis and cardiac enlargement. Bio-impedance 
spectroscopy device is a more sensitive tool than IVCD measurement for the assessment of fluid 
status in clinically euvolaemic non-dialytic stage 3 CKD patients. The findings suggest that the 
atherogenic predictive power of endotoxin is significantly increased by the presence of high 
concentrations of immune mediators in CKD patients. The increased risk of atherosclerosis in 
CKD patients was demonstrated to be due to the inflammation mediated by endotoxin, with 
protection afforded by TGB-β. Furthermore, there is a close association between IL-6 
polymorphisms (G/G and G/C) and elevated serum IL-6 levels in CKD patients.  
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